Portal de investigación
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Bilton D
- Pressler T
- Fajac I
- Clancy JP
- Sands D
- Minic P
- Cipolli M
- Galeva I
- Quittner AL
- Liu K
- McGinnis JP
- Eagle G
- Gupta R
- Konstan MW
- CLEAR-108 Study Group
Grupos
Abstract
Shortcomings of inhaled antibiotic treatments for Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) include poor drug penetration, inactivation by sputum, poor efficiency due to protective biofilm, and short residence in the lung.
Datos de la publicación
- ISSN/ISSNe:
- 1569-1993, 1873-5010
- Tipo:
- Article
- Páginas:
- 284-291
- PubMed:
- 31451351
- Factor de Impacto:
- 2,049 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society ELSEVIER SCIENCE BV
Citas Recibidas en Web of Science: 25
Documentos
- No hay documentos
Filiaciones
Keywords
- ALIS, Amikacin liposome inhalation suspension, CFQ-R, Cystic fibrosis, LAI, Liposomal amikacin for inhalation, Pseudomonas aeruginosa
Campos de Estudio
Cita
Bilton D,Pressler T,Fajac I,Clancy JP,Sands D,Minic P,Cipolli M,Galeva I,SOLÉ A,Quittner AL,Liu K,McGinnis JP,Eagle G,Gupta R,Konstan MW,CLEAR G. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros. 2020. 19. (2):p. 284-291. IF:5,482. (1).